205 related articles for article (PubMed ID: 37607999)
21. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.
Nielsen MF; Mortensen MB; Detlefsen S
World J Gastroenterol; 2016 Mar; 22(9):2678-700. PubMed ID: 26973408
[TBL] [Abstract][Full Text] [Related]
22. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Interplay Between Cancer Fibroblasts, Mesenchymal Stem Cells, and Cancer Stem Cells in Desmoplastic Cancers.
Chan TS; Shaked Y; Tsai KK
Front Oncol; 2019; 9():688. PubMed ID: 31417869
[TBL] [Abstract][Full Text] [Related]
24. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen.
Ogawa Y; Masugi Y; Abe T; Yamazaki K; Ueno A; Fujii-Nishimura Y; Hori S; Yagi H; Abe Y; Kitago M; Sakamoto M
Clin Cancer Res; 2021 Jan; 27(1):107-119. PubMed ID: 33046515
[TBL] [Abstract][Full Text] [Related]
25. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
[TBL] [Abstract][Full Text] [Related]
26. PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer.
Kawasaki K; Noma K; Kato T; Ohara T; Tanabe S; Takeda Y; Matsumoto H; Nishimura S; Kunitomo T; Akai M; Kobayashi T; Nishiwaki N; Kashima H; Maeda N; Kikuchi S; Tazawa H; Shirakawa Y; Fujiwara T
Cancer Immunol Immunother; 2023 Nov; 72(11):3787-3802. PubMed ID: 37668710
[TBL] [Abstract][Full Text] [Related]
27. Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment.
Wang Y; Fang X; Li M; Ye J; Zhao S; Yu L; Wang J; Wang Y; Yan Z
Cancer Genet; 2022 Nov; 268-269():103-110. PubMed ID: 36288641
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
29. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
31. Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control.
Zhen Z; Tang W; Wang M; Zhou S; Wang H; Wu Z; Hao Z; Li Z; Liu L; Xie J
Nano Lett; 2017 Feb; 17(2):862-869. PubMed ID: 28027646
[TBL] [Abstract][Full Text] [Related]
32. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
33. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors.
Otahal P; Knowles BB; Tevethia SS; Schell TD
J Immunol; 2007 Nov; 179(10):6686-95. PubMed ID: 17982058
[TBL] [Abstract][Full Text] [Related]
35. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
36. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.
Sandberg TP; Stuart MPME; Oosting J; Tollenaar RAEM; Sier CFM; Mesker WE
BMC Cancer; 2019 Mar; 19(1):284. PubMed ID: 30922247
[TBL] [Abstract][Full Text] [Related]
38. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.
Fearon DT
Cancer Immunol Res; 2014 Mar; 2(3):187-93. PubMed ID: 24778314
[TBL] [Abstract][Full Text] [Related]
39. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling.
Yang X; Lin Y; Shi Y; Li B; Liu W; Yin W; Dang Y; Chu Y; Fan J; He R
Cancer Res; 2016 Jul; 76(14):4124-35. PubMed ID: 27216177
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).
Markosyan N; Li J; Sun YH; Richman LP; Lin JH; Yan F; Quinones L; Sela Y; Yamazoe T; Gordon N; Tobias JW; Byrne KT; Rech AJ; FitzGerald GA; Stanger BZ; Vonderheide RH
J Clin Invest; 2019 Jun; 129(9):3594-3609. PubMed ID: 31162144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
